Among patients over 65 who received an allogeneic hematopoietic stem cell transplant (allo-HCT) for the treatment of acute myeloid leukemia (AML) between 2000 and 2021, leukemia-free and overall survival improved significantly over time.
PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders
PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™.